|Grant Number:||5R01CA080181-04 Interpret this number|
|Primary Investigator:||Hartmann, Lynn|
|Project Title:||Prophylctic Mastectomy in Hereditary Breast Cancer|
DESCRIPTION: (Adapted from the Investigator's Abstract) Women with hereditary breast cancer risk have limited options for management. Close cancer screening or prophylactic mastectomy (PM) is most commonly utilized. Chemoprevention with tamoxifen is another option, but data regarding long-term risk reduction are incomplete and conflicting. Unfortunately, there are insufficient data regarding the expected outcomes with either surveillance or PM. Breast cancers on the chest wall have been documented following PM, developing in residual glandular epithelium. Thus, the extent of risk reduction with PM, if any, has been questioned. The program announcement "Clinical Epidemiology Studies in Hereditary Breast/Ovarian Cancer" describes the "immediate need to address these issues through retrospective studies based on existing resources". The Mayo Clinic has served as a referral center for specialized surgeries, including PM, for many years. They have access to two groups of high-risk women who elected PM: unaffected women who have elected contralateral PM and women treated with therapeutic mastectomy for their first breast cancer who elected contralateral, unilateral PM. With the work proposed, the investigators will clarify the magnitude of breast cancer risk reduction with PM using a combination of methods, including standardized morbidity ratios using the Gail and Anderson models to predict the expected number of events, and a relative risk using sisters of women who had PM as a reference group. We will also define short- and long-term complications following PM.
Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.
Authors: Mutter R.W. , Frost M.H. , Hoskin T.L. , Johnson J.L. , Hartmann L.C. , Boughey J.C. .
Source: Breast cancer research and treatment, 2015 Aug; 153(1), p. 183-90.
EPub date: 2015-07-26.
Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits.
Authors: Frost M.H. , Hoskin T.L. , Hartmann L.C. , Degnim A.C. , Johnson J.L. , Boughey J.C. .
Source: Annals of surgical oncology, 2011 Oct; 18(11), p. 3110-6.
EPub date: 2011-09-27.
Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer.
Authors: Boughey J.C. , Hoskin T.L. , Degnim A.C. , Sellers T.A. , Johnson J.L. , Kasner M.J. , Hartmann L.C. , Frost M.H. .
Source: Annals of surgical oncology, 2010 Oct; 17(10), p. 2702-9.
EPub date: 2010-09-19.
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Authors: Adem C. , Soderberg C.L. , Hafner K. , Reynolds C. , Slezak J.M. , Sinclair C.S. , Sellers T.A. , Schaid D.J. , Couch F. , Hartmann L.C. , et al. .
Source: Genes, chromosomes & cancer, 2004 Sep; 41(1), p. 1-11.
Reoperations after prophylactic mastectomy with or without implant reconstruction.
Authors: Zion S.M. , Slezak J.M. , Sellers T.A. , Woods J.E. , Arnold P.G. , Petty P.M. , Donohue J.H. , Frost M.H. , Schaid D.J. , Hartmann L.C. .
Source: Cancer, 2003-11-15; 98(10), p. 2152-60.
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
Authors: Riggs B.L. , Hartmann L.C. .
Source: The New England journal of medicine, 2003-02-13; 348(7), p. 618-29.
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
Authors: Sinclair C.S. , Adem C. , Naderi A. , Soderberg C.L. , Johnson M. , Wu K. , Wadum L. , Couch V.L. , Sellers T.A. , Schaid D. , et al. .
Source: Cancer research, 2002-07-01; 62(13), p. 3587-91.
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
Authors: McDonnell S.K. , Schaid D.J. , Myers J.L. , Grant C.S. , Donohue J.H. , Woods J.E. , Frost M.H. , Johnson J.L. , Sitta D.L. , Slezak J.M. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-10-01; 19(19), p. 3938-43.